The vaccine used to protect humans against the anthrax disease, called Anthrax Vaccine Adsorbed (AVA), was licensed in 1970. It was initially used to protect people who might be exposed to anthrax where they worked, such as veterinarians and textile plant workers who process animal hair. When the U. S. military began to administer the vaccine, then extended a plan for the mandatory vaccination of all U. S. service members, some raised concerns about the safety and efficacy of AVA and the manufacture of the vaccine. In response to these and other concerns, Congress directed the Department of Defense to support an independent examination of AVA.
The Anthrax Vaccine: Is It Safe? Does It Work? reports the study’s conclusion that the vaccine is acceptably safe and effective in protecting humans against anthrax. The book also includes a description of advances needed in main areas: improving the way the vaccine is now used, expanding surveillance efforts to detect side effects from its use, and developing a better vaccine.
Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. https://doi.org/10.17226/10310.
|3 Anthrax Vaccine Efficacy||56-82|
|4 Safety: Introduction||83-101|
|5 Safety: Case Reports||102-117|
|6 Safety: Epidemiologic Studies||118-179|
|7 Anthrax Vaccine Manufacture||180-197|
|8 Future Needs||198-210|
|Appendix A Statement of Task||211-213|
|Appendix B Biographical Sketches||214-217|
|Appendix C Information-Gathering Meeting Agendas||218-226|
|Appendix D Anthrax Vaccine Adsorbed Package Inserts||227-238|
|Appendix E Vaccine Adverse Event Reporting System (VAERS) Form||239-242|
|Appendix F Anthrax Vaccine Expert Committee (AVEC) Case Assessment Form||243-244|
|Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine||245-252|
|Appendix H An Assessment of the Safety of the Anthrax Vaccine: A Letter Report||253-266|
The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.